Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature ReviewDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsEffect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trialsSoluble epoxide hydrolase inhibitors and heart failureImpairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991.A U-shaped association of body mass index and all-cause mortality in heart failure patients: A dose-response meta-analysis of prospective cohort studies.Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.Impact of antioxidant supplementations on cardio-renal protection in cardiac surgery: an updated and comprehensive meta-analysis and systematic review.Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry.Natural antioxidants and hypertension: promise and challenges.Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients.Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina.Liver X receptors (LXR) as therapeutic targets in dyslipidemia.Nutraceuticals in diabetes and metabolic syndrome.Safety of herbal supplements: a guide for cardiologists.5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.Clopidogrel "resistance": where are we now?Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsNew antithrombotics for atrial fibrillation.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.eNOS overexpressing bone marrow cells are safe and effective in a porcine model of myocardial regeneration following acute myocardial infarction.Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart modelGeometry of the randomized evidence for treatments of pulmonary hypertension.Vitamin D versus placebo in improvement of endothelial dysfunction: a meta-analysis of randomized clinical trials.Estrogen receptor beta does not influence ischemic tolerance in the aged female rat heart.TPEN prevents rapid pacing-induced calcium overload and nitration stress in HL-1 myocytes.A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction.Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease.Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor.Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large single-center data.The cardiovascular effects of GLP-1 receptor agonists.
P1433
Q28073813-8E6F96BC-7ABB-40CA-9947-EB15C4BEDFEEQ28238585-323B9CCB-9C9B-472A-A9DB-53F7A84EBCF3Q28256514-DF1250E4-9EE6-4218-AF2D-B0F2E39EE040Q28383423-D2833727-DB6A-40B1-9A35-DBE098FD13CBQ29346972-962AD6FC-E501-4175-8263-9A6816AE7E06Q30244073-696BC243-B1CA-4FF0-B006-DE3F681EE689Q30248398-50AB8653-1767-4721-8332-FC0462FD7BE6Q30248710-6B302049-7A1A-41DD-89A8-116C795EBEA3Q30249324-0311A09D-6ABB-4924-A895-CD754219101BQ30275124-68630DF1-DAD9-4E8F-A5DA-4C12BAF00B26Q30615846-54D069E4-CA4E-4BB5-ACEB-E1975D5B87F9Q34001067-66DBA5AE-E961-4E00-88D6-49440810AD46Q34007711-01C6941E-8FB7-425F-AB7C-BC9082277754Q34007717-23E39F49-6018-4615-9081-91141D1E3E73Q34007774-73DB60A5-F02E-4F37-AE4B-166D0F73883CQ34014852-9BA2DEBA-0396-4D58-8C83-A5BA9F9B56E8Q34126103-2253906F-D765-4B74-A566-9594344146E6Q34126109-D75C6F04-73B1-476E-8AA5-521284A98373Q34145991-B6DA09E2-7DDC-4388-8274-8DAB1CF475F4Q34167806-4E4FFD74-CD4A-40BE-B526-A08F95B58516Q34212563-05BD74B9-D662-491C-B981-001094F2C314Q34217461-A28477BA-55F6-4247-A396-2FCD4515E7FBQ34621696-BBC221A8-554B-4570-987E-FEC8701C09DDQ34631971-C1F6ACDA-1D3E-4378-8C00-47AFE8F91320Q34669942-1BD0D12E-8E40-4E5D-B1F9-AE22F2CEB3A0Q34803600-44B89917-7AA4-496C-A20D-95044D734848Q34853000-D82F1955-C924-4B7B-A5E3-AE7127E6D95BQ35013676-851F6CBB-FF0D-4D61-9ADB-93DF30F70D04Q35596938-9BA6812F-5E46-4DBA-92F3-2197DE8DC9AFQ35605843-5834BC31-2CB1-452C-A52F-BF86E0EF6600Q35631361-88D76900-F2E7-42D0-99A5-66E3E3422FC6Q35633171-8A6AC999-AD29-4219-BDCF-397F5725EA7EQ35836747-EAD3C2E7-B351-42C7-A859-65AD41F519AEQ35869541-2D245CB7-0CCA-4AE0-AD39-85F9D00E4302Q36142335-DFFD0A83-7F34-495C-8653-2DEA4F6ECF4BQ36205310-01A6BDAA-AA26-4EDD-B005-CE9F4B06E6DBQ36276804-D2AB3F55-E39C-42CD-A63F-92B9F4972B0EQ36351044-B799D4D5-E16F-4AF7-915B-5CE4E550D0CBQ36362082-2860DED8-F97D-458F-B870-459982666573Q36368998-D71817E8-5496-4467-B486-68AD8CBC2E16
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Wiley-Blackwell
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
वैज्ञानिक पत्रिका
@hi
name
Cardiovascular Therapeutics
@da
Cardiovascular Therapeutics
@de
Cardiovascular Therapeutics
@en
Cardiovascular Therapeutics
@es
Cardiovascular Therapeutics
@fi
Cardiovascular Therapeutics
@fr
Cardiovascular Therapeutics
@it
Cardiovascular Therapeutics
@nb
Cardiovascular Therapeutics
@nl
Cardiovascular Therapeutics
@nn
type
label
Cardiovascular Therapeutics
@da
Cardiovascular Therapeutics
@de
Cardiovascular Therapeutics
@en
Cardiovascular Therapeutics
@es
Cardiovascular Therapeutics
@fi
Cardiovascular Therapeutics
@fr
Cardiovascular Therapeutics
@it
Cardiovascular Therapeutics
@nb
Cardiovascular Therapeutics
@nl
Cardiovascular Therapeutics
@nn
prefLabel
Cardiovascular Therapeutics
@da
Cardiovascular Therapeutics
@de
Cardiovascular Therapeutics
@en
Cardiovascular Therapeutics
@es
Cardiovascular Therapeutics
@fi
Cardiovascular Therapeutics
@fr
Cardiovascular Therapeutics
@it
Cardiovascular Therapeutics
@nb
Cardiovascular Therapeutics
@nl
Cardiovascular Therapeutics
@nn
P31
P3181
P1055
P1058
P1156
11900154314
P1250
P1277
P1476
Cardiovascular Therapeutics
@und
P236
P3181
P407
P5115
P571
2008-01-01T00:00:00Z